Estimating Risks of De Novo Kidney Diseases After Living Kidney Donation

De novo postdonation renal diseases, such as glomerulonephritis or diabetic nephropathy, are infrequent and distinct from the loss of GFR at donation that all living kidney donors experience. Medical findings that increase risks of disease (e.g. microscopic hematuria, borderline hemoglobin A1C) often prompt donor refusal by centers. These risk factors are part of more comprehensive risks of low GFR and end‐stage renal disease (ESRD) from kidney diseases in the general population that are equally relevant. Such data profile the ages of onset, rates of progression, prevalence and severity of loss of GFR from generically characterized kidney diseases. Kidney diseases typically begin in middle age and take decades to reach ESRD, at a median age of 64. Diabetes produces about half of yearly ESRD and even more lifetime near‐ESRD. Such data predict that (1) 10‐ to 15‐year studies will not capture the lifetime risks of postdonation ESRD; (2) normal young donors are at demonstrably higher risk than normal older candidates; (3) low normal predonation GFRs become risk factors for ESRD when kidney diseases arise and (4) donor nephrectomy always increases individual risk. Such population‐based risk data apply to all donor candidates and should be used to make acceptance standards and counseling more uniform and defensible.

[1]  F. Dekker,et al.  Long-term risks for kidney donors. , 2014, Kidney international.

[2]  J. Coresh,et al.  Lifetime incidence of CKD stages 3-5 in the United States. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  T. Wilt,et al.  Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  D. Mandelbrot,et al.  Living donor practices in the United States. , 2012, Advances in chronic kidney disease.

[5]  S. Satchell,et al.  Diabetic nephropathy. , 2012, Clinical medicine.

[6]  J. Craig,et al.  Screening and Follow-Up of Living Kidney Donors: A Systematic Review of Clinical Practice Guidelines , 2011, Transplantation.

[7]  C. Young,et al.  Ethnic and Gender Related Differences in the Risk of End‐Stage Renal Disease After Living Kidney Donation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  Patrick J Heagerty,et al.  Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.

[9]  M. Schnitzler,et al.  Racial variation in medical outcomes among living kidney donors. , 2010, The New England journal of medicine.

[10]  R. Steiner ‘Normal for Now’ or ‘At Future Risk’: A Double Standard for Selecting Young and Older Living Kidney Donors , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  N. Powe,et al.  Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[12]  Desmond E. Williams,et al.  A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Y. Shibagaki,et al.  How Do Living Kidney Donors Develop End‐Stage Renal Disease? , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  W. Weimar,et al.  Long-term consequences of kidney donation. , 2009, The New England journal of medicine.

[15]  Stian Lydersen,et al.  Combining GFR and albuminuria to classify CKD improves prediction of ESRD. , 2009, Journal of the American Society of Nephrology : JASN.

[16]  A. Kesselheim,et al.  Creating a medical, ethical, and legal framework for complex living kidney donors. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[17]  G. Mayer,et al.  Evaluation of the living kidney donor. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  C. Gullion,et al.  Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. , 2004, Archives of internal medicine.

[19]  G. Danovitch,et al.  The Medical Evaluation and Risk Estimation of End Stage Renal Disease for Living Kidney Donors , 2004 .

[20]  Stephen W. Sorensen,et al.  Lifetime risk for diabetes mellitus in the United States. , 2003, JAMA.

[21]  Chi-yuan Hsu,et al.  Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective , 2002, Current opinion in nephrology and hypertension.

[22]  L. Agodoa,et al.  United States Renal Data System (USRDS). , 2000, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[23]  E. Ritz,et al.  Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.

[24]  R. Sorelle United Network for Organ Sharing. , 1997, Circulation.

[25]  J. Curtis,et al.  Clinical documentation of end-stage renal disease due to hypertension. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[27]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[28]  E. A. Hildreth,et al.  OCCULT PRIMARY RENAL DISEASE IN THE HYPERTENSIVE PATIENT. , 1964, Archives of internal medicine.